Sensus Healthcare, Inc
SRTSStock
$3.02−26.67%52W
Market Cap$50.04M
P/E9.63x
Div yield—
Beta1.13
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-39.30%
Price vs S&P 500 (4W)13.06%
VGM Score44.99
Market Capitalization$50.04M
P/E Ratio (Annual)9.63x
Earnings Surprise History
Q1 26-0.16est. -0.13
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.10
4.10
4.10
4.10
Industry Peers — Surgical & Medical Instruments(141)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SRTSSensus Healthcare, Inc | B | D | D | $3.02 |
| SYKStryker Corporation | C | C | D | $331.20 |
| MMM3M Company | C | F | B | $161.77 |
| BSXBoston Scientific Corp. | C | B | F | $44.62 |
| MDLNMedline Inc. Class A common stock | C | D | D | $41.11 |
| BDXBecton, Dickinson and Co. | B | C | B | $159.93 |
| DXCMDexCom, Inc. | C | B | C | $77.98 |
| RMDResMed Inc. | C | B | D | $202.76 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | $362.44 |
| SOLVSolventum Corporation | C | D | B | $81.70 |
| PENPenumbra, Inc. | F | C | B | $319.60 |
About
Sensus Healthcare manufactures superficial radiotherapy (SRT) systems for treating skin cancers and non-cancerous skin conditions. The company's products, including the SRT-100 and SRT-100 Vision platforms, address dermatological applications such as basal cell carcinoma, squamous cell carcinoma, and keloids. Revenue is generated primarily from U.S. customers.